Patient-reported impact of Charcot-Marie-Tooth disease: protocol for a real-world digital lifestyle study.
Florian P ThomasMario SaportaShahram AttarianTeresa SevillaRafael Sivera MascaróGian Maria FabriziFilippo GenoveseAmy GraySimon BullDaniel TanesseManuel RegoAllison MooreCourtney HollettKatia MonteiroXavier PaoliSamuel LlewellynMark LarkinYoucef BoutalbiPublished in: Neurodegenerative disease management (2020)
Charcot-Marie-Tooth disease (CMT) is a rare, chronic, progressive motor and sensory neuropathy affecting the peripheral nervous system. This study will explore the real-world impact of CMT. The trial is a digital study of approximately 2000 people in 6 countries with CMT ≥18 years. Participants will use a smartphone application to check eligibility, provide consent and contribute data. The dataset will include a personal profile, covering demographics, lifestyle, diagnosis and treatment and a selection of validated generic and disease-specific instruments. Participants will provide data for up to 2 years. Data analysis will be conducted upon registration of the 1000th participant and at 12-month intervals from launch. This study is designed to help researchers and clinicians understand the real-world impact of CMT and the unmet needs of patients. ClinicalTrials.gov identifier: NCT03782883.